在这种情况下，我们分享我们如何与之合作 Med. 螺纹实验室 到 递送 '帕多森' - 一种新的糖尿病和高血压综合护理模型。
79% of people living with diabetes are in low- and middle-income countries – a disease that kills 4.2 million people per year. The majority are unable to access the affordable medicines, diagnostics and education they need. 4 in 5 people with diabetes in low- and middle-income countries are undiagnosed.
In these rural populations, there is a lack of education and diagnosis of diabetes and hypertension. As a resident in the areas, you typically have to travel long distances to expensive private clinics for basic tests for glucose, HbA1C and cholesterol. A comprehensive panel costs approximately $50 in a private hospital or outpatient diagnostic centre, 10 times more than the average daily earning of a community resident.
reach52 collaborated with Medtronic LABS to launch a new diabetes and hypertension model of care in rural Philippines. The ‘Padayon’ (meaning ‘Keep Moving Forward’) programme empowers patients to continue to live their life though access to the quality testing, medicines and coaching support they need.
This integrated care model combines regular testing, affordable medicines (through reach52 marketplace) and practical coaching all together in one accessible service for residents. The service was developed in partnership with the Pototan Municipal Health Officer, and community health nurses have been equipped as the ‘Padayon’ health coaches .
The programme is currently being piloted in Pototan in the Western Visayas, starting with local screening sessions for undiagnosed patients and the engagement of existing diabetic patients in these rural communities.
Patients enrol in an affordable 12 week programme, through which they receive blood glucose monitoring, affordable medicines via reach52’s marketplace service, and coaching from trained health coaches.
The coaching programme combines live group sessions, digital learning and peer support to motivate lifestyle change, medication adherence, and prevent complications.
After the initial 12-week programme, patients can continue to subscribe to monthly medications and digital health services through Facebook Messenger.
Pilot still in progress.
The pilot target outcomes are to deliver measurable changes in patient’s Fasting Blood Sugar (FBS), HbA1C, and systolic / diastolic blood pressure, as well as knowledge of diabetes and hypertension management.
The programme was launched in October 2020, and the findings and learnings of this pilot will be reported in January. with plans to roll out the ‘Padayon’ service across new regions in 2021.
So far, over 300 patients have been screened and the target +60 patient signed up to the paid-subscription programme for month 1.
“High-value partnerships are more important than ever before, and our work with reach52 shows how this might be done efficiency and effectively. The Padayon programme combines best in-class technology, a tested curriculum based on behavioral science, and excellence in local implementation to help patients achieve health outcomes. ‘Padayon’ paves the way for future collaboration as we work towards our shared goal of improving health outcomes for underserved patients.”
Anne Stake, Head of Strategy and Innovation at Medtronic LABS
79％的人患有糖尿病处于低收入和中等收入国家 - 一种疾病，每年杀死420万人。大多数人无法访问这经济实惠的药物，诊断和他们需要的教育。4人中有5人，低收入中等收入国家的糖尿病是未确诊的。